Exchange Surveillance
- ASM Stage IVLong Term Additional Surveillance Measure (LTASM) - Stage IV
Price band ± 5% · narrower than the standard 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Bliss GVS Pharma Ltd.is engaged in the manufacture of a wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.The companys most unique product is Today Vaginal Contraceptive, a safe female contraceptive .The Prescription drugs of the company include Alaxin, Gvither, P-Alaxin, Gsunate and Lonart ,Rectol, Poroxicam, Parafen, Vomitin, Slipizem, AnomexProchloperazine, Imazole, Gvgyl, Terconazole, Vagid, Gvgyl - N, etc. and over the counter products are Today Regular, Today Economy, Today Premium.Maitri Vaginal Lubricant Pessary,etc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Mumbai, Maharashtra
- Chairman
- S R Vaidya
- CEO & MD
- Gagan Harsh Sharma
- Registrar
- Universal Capital Securities Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE416D01022
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Bliss GVS Pharma Ltd today?
Bliss GVS Pharma Ltd (BLISSGVS) is trading at ₹623.35. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is BLISSGVS’s P/E ratio versus the sector?
BLISSGVS trades at a P/E of 60.2. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is BLISSGVS’s dividend yield?
BLISSGVS has a dividend yield of 0.23%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is BLISSGVS’s 52-week high and low?
BLISSGVS has traded between ₹118 and ₹739.9 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has a market capitalisation of ₹6,975 crore.
▶What is BLISSGVS’s return on equity?
BLISSGVS reports a return on equity of 8.9%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are BLISSGVS’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is BLISSGVS’s promoter holding?
Promoters hold 35.01% of BLISSGVS. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include BLISSGVS?
Index membership is listed in the Context block on this page, along with the weight BLISSGVS carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Bliss GVS Pharma Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from BLISSGVS’s own numbers. The judgement is yours.
BLISSGVS at a glance
Bliss GVS Pharma Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Bliss GVS Pharma Ltd (BLISSGVS) last traded at ₹623.35, giving it a market capitalisation of ₹6,975 crore. The 52-week range is ₹118 to ₹739.9, and the price is 81% of the way up that range. It trades at a price-to-earnings ratio of 60.2. Promoters hold 35.01% of the company in the latest shareholding filing.
| Market cap | ₹6,975 crore |
|---|---|
| P/E | 60.2 |
| ROE | 8.9% |
| ROCE | 12.8% |